Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1391972 10.3389/fphar.2024.1391972 Pharmacology Original Research Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents Jin et al. 10.3389/fphar.2024.1391972 Jin Xuanhong 1 † Pan Yang 2 † Cheng Cheng 3 Shen Hangchen 1 Zhai Chongya 1 Yin Kailai 2 Zhu Xinyu 2 Pan Hongming 1 * You Liangkun 1 * 1 Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China 2 Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, China 3 Department of Clinical Laboratory, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China

Edited by: Shiyou Wei, Sichuan University, China

Reviewed by: Hashem Obaid Alsaab, Taif University, Saudi Arabia

Pasquale Pisapia, University of Naples Federico II, Italy

 *Correspondence: Hongming Pan, panhongming@zju.edu.cn; Liangkun You, youliangkun@zju.edu.cn

These authors have contributed equally to this work and share first authorship

 05 08 2024 2024 15 1391972 26 02 2024 26 07 2024 Copyright © 2024 Jin, Pan, Cheng, Shen, Zhai, Yin, Zhu, Pan and You. 2024 Jin, Pan, Cheng, Shen, Zhai, Yin, Zhu, Pan and You

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 Background

In individuals receiving treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), those exhibiting positive PD-L1 expression might experience reduced progression-free survival (PFS). However, the effects on overall survival (OS) and the determination of efficacious treatment approaches are still not well-defined.

 Methods

In our retrospective study, we examined data from 193 NSCLC patients with advanced EGFR mutations who received first-line TKI treatments, treated at two centers of Shaw Hospital in Zhejiang, China. This analysis covered a period from 1 January 2016 to 30 April 2023.

 Results

Patients with PD-L1 positivity exhibited a markedly shorter average PFS (9.5 months versus 17.8 months, P < 0.001) and OS (44.4 months versus 65.7 months, P = 0.016) relative to those without PD-L1 expression. This difference in both PFS and OS remained statistically significant even after adjusting for multiple factors (P < 0.001 for PFS and P = 0.028 for OS). In the PD-L1-positive cohort, introducing combination antiangiogenic significantly extended both PFS (from 9.1 to 25.7 months, P = 0.026) and OS (from 42 to 53.5 months, P = 0.03). Post-first-line TKI therapy, 39.3% of PD-L1-positive patients and 54.5% of PD-L1-negative patients developed the T790M mutation (P = 0.212), with no notable difference in PFS from second-line TKI treatments between the groups. Additionally, subsequent combination therapy with immunotherapy markedly prolonged OS in the PD-L1-positive group. However, for PD-L1-negative patients, neither combination antiangiogenic therapy nor later-line immunotherapy demonstrated significant benefits in PFS or OS.

 Conclusion

For PD-L1-positive patients, combined antiangiogenic treatments and immunotherapy can significantly improve survival outcomes. In contrast, PD-L1-negative patients show less benefit from these therapies, highlighting the greater efficacy of these treatments in PD-L1-positive individuals.

 NSCLC EGFR TKIs PD-L1 antiangiogenic therapy immunotherapy section-at-acceptance Pharmacology of Anti-Cancer Drugs Introduction

Mutations in the epidermal growth factor receptor (EGFR) are common in non-small cell lung cancer (NSCLC), accounting for approximately 50% of cases in Asians and 25% in Caucasians (Lynch et al., 2004). These mutations are particularly prevalent in East Asian lung adenocarcinoma patients, females, and non-smokers (Shi et al., 2014). The introduction of EGFR tyrosine kinase inhibitors (TKIs) has transformed the therapeutic approach for advanced NSCLC patients with EGFR mutations, establishing them as the primary treatment option and significantly enhancing survival (Rosell et al., 2012). Despite the development of third-generation TKIs targeting the T790M resistance mutation (Mok et al., 2017), early resistance continues to be a major issue for many patients. Current research is focused on understanding the causes of this resistance and finding effective ways to counter it.

In the precision medicine era, the use of immune checkpoint inhibitors (ICIs) has significantly altered the approach to treating NSCLC (Mok et al., 2019). However, in patients with EGFR-mutant NSCLC, PD-L1 expression is generally lower (Soo et al., 2018), which correlates with less effective responses to ICIs in this subset (Gainor et al., 2016). Previous studies have shown that PD-L1 positive and negative patients have distinct molecular landscapes, which may significantly impact patient treatment and prognosis (Pisapia et al., 2022). Recent meta-analyses indicate that patients with PD-L1 positivity tend to have shorter progression-free survival (PFS) when treated with first-line EGFR TKIs (Peng et al., 2021). This is further evidenced by various studies examining the relationship between PFS, PD-L1 expression, and the use of third-generation TKIs (Yoshimura et al., 2021; Hsu et al., 2022; Hamakawa et al., 2023). The link between PD-L1 expression and overall survival (OS) in EGFR mutation-positive patients remains unclear. Some research suggests that PD-L1 positivity could be indicative of a poorer prognosis in these patients (Lin et al., 2015; Liu et al., 2021). Particularly, data on the PD-L1 status and OS in patients treated with third-generation TKIs are still lacking. Moreover, there is also research that points to PD-L1 positivity being associated with a reduced occurrence of the T790M mutation following first-line TKI therapy (Yang et al., 2020; Inomata et al., 2022), which might affect the selection and effectiveness of subsequent second-line treatments.

In the JO25567 phase II study and the NEJ026 phase III study, first-line erlotinib in combination with bevacizumab significantly prolonged PFS but did not show a significant benefit in OS (Seto et al., 2014; Saito et al., 2019). In contrast, some retrospective studies have shown that first-line or further-line combination bevacizumab can improve OS in patients treated with first-line TKIs (Tsai et al., 2021; You et al., 2022). Additionally, combining small molecule antiangiogenic agents such as anlotinib and apatinib is also a feasible strategy after progression on first-line TKIs (Han et al., 2024). A Taiwanese study specifically showed an OS benefit for patients with EGFR mutations only in those with poor prognostic factors, when treated with combination antiangiogenic therapy and first-line TKIs (Chen et al., 2022). Therefore, combination antiangiogenic therapy may be a promising option for patients with PD-L1 positivity.

We conducted a retrospective study aiming to determine the effect of PD-L1 status on prognosis among different subgroups of patients with EGFR mutations who received first-line TKI therapy, particularly whether PD-L1 status influences OS. We also compared the PFS benefit of first-line TKI combined with antiangiogenic therapy versus first-line TKI alone. Additionally, we evaluated the potential effects of antiangiogenic therapy and further-line immunotherapy on the OS of patients with varying PD-L1 statuses. Our study aims to provide tailored treatment strategies for clinical practice in first-line TKI therapy based on different PD-L1 statuses.

 Methods Research design and participant selection

This retrospective study was conducted at two facilities of Sir Run Run Shaw Hospital at Zhejiang University (Qingchun Hospital and Xiasha Hospital). It was ethically approved by the Ethics Committee of Sir Run Run Shaw Hospital, affiliated with the Zhejiang University School of Medicine, under the reference number 2024-2002-01. This approval ensured compliance with the ethical guidelines stipulated in the Declaration of Helsinki. Due to the retrospective nature of the research, the requirement for informed consent was waived by the Ethics Committee of Sir Run Run Shaw Hospital.

This research involved 193 lung cancer patients, enrolled between 1 January 2016, and 30 April 2023. The criteria for inclusion were: 1) Histologically verified NSCLC, 2) Stage III or IV lung cancer classification as per the 8th edition of the AJCC staging system, 3) Detection of an EGFR mutation, either an EGFR exon 21 p.L858R substitution or an EGFR exon 19 deletion, 4) Initial treatment with TKIs, and 5) Use of at least one standard chemotherapy regimen after TKI resistance. Exclusion criteria encompassed patients with alternate mutations or those who had undergone systemic treatment before starting TKI therapy.

Data collection in this study covered various demographic and clinical factors, including age, sex, smoking status, Eastern Cooperative Oncology Group Performance Status (ECOG PS) scores, clinical stage, and initial presence of brain or bone metastases and treatment regimen. The study also meticulously documented EGFR mutation status, any subsequent resistance mutations, and PD-L1 expression levels.

Details regarding the treatment regimen were comprehensively recorded, focusing on the first-line therapy administered to participants. The study tracked PFS during and after the TKI treatment period, alongside OS post-TKI therapy. PFS was measured from the beginning of TKI treatment until disease progression or death, whereas OS was determined from the start of TKI therapy until death.

 Antiangiogenic therapy and immunotherapy

Patients receiving combination antiangiogenic therapy have been treated in the first-line or subsequent-line, whereas combination immunotherapy have been treated in the subsequent-line only. First-line treatment is defined as the first systemic therapy given after diagnosis. Subsequent-line treatment is defined as any subsequent anticancer therapy administered after disease progression. The use of antiangiogenic agents and immunotherapy in first- and subsequent-line treatments is detailed in the Supplementary Table S1. Antiangiogenic drugs included bevacizumab (15 mg/kg once every 3 weeks), anlotinib (12 mg or 10 mg in 3-week cycles), and apatinib (500 mg in 4-week cycles). Immunotherapy is administered with anti-PD-1 or PD-L1 antibodies, including sintilimab (200 mg every 3 weeks), nivolumab (3 mg/kg every 2 weeks), pembrolizumab (200 mg/kg every 3 weeks), durvalumab (1,500 mg every 3 weeks), toripalimab (3 mg/kg every 3 weeks), or atezolizumab (1,200 mg every 3 weeks).

 PD-L1 expression and <italic>EGFR</italic> mutation analysis

PD-L1 immunohistochemistry (IHC) expression in tumor cells was determined using either the Ventana SP263 monoclonal antibody kit or the Dako 22C3 pharmDx kit. PD-L1 expression was categorized as positive when it was equal to or exceeded 1%, and as negative when it was below this threshold. For identifying EGFR mutations, our facility’s pathology department, or a third-party genetic testing service accredited by the College of American Pathologists (CAP), conducts genetic alteration tests on tumor tissues or cells. These samples are typically obtained through biopsy, surgical resection, or the centrifugation of pleural effusion sediments. The testing methodologies employed include NGS (Illumina) and polymerase chain reaction (PCR) techniques.

 Statistical analyses methods

For assessing differences in clinical characteristics between PD-L1 subgroups, the chi-square test was utilized. PFS and OS were estimated using the Kaplan-Meier method for survival analysis. Subgroup and interaction tests were conducted using the “jstable” function in R software. The Cox proportional hazards model was employed to evaluate survival time differences in PFS and OS. If univariate regression analysis shows a significant difference (P < 0.05), those variables will be included in the multivariate regression analysis. Statistical significance was determined using two-tailed tests, with P < 0.05 as the threshold for significance. Past statistical research indicates that in exploratory studies or when dealing with limited sample sizes, it is reasonable to use a looser significance level in interaction tests (Núñez et al., 2011). Therefore, in our interaction tests, a significance level of P < 0.1 was considered meaningful, specifically for interaction effects.

 Results Patient characteristics

The clinical characteristics of the 193 patients included in this study are described in Table 1, the median follow-up of the patients was 27.3 (1.4–89.2) months, all patients had adenocarcinomas, 121 (62.7%) patients were negative for PD-L1 status while 72 (37.3%) patients were positive for PD-L1 expression, 147 (76.1%) of them used 22C3 antibody test while 46 (23.9%) patients were tested with SP263 antibody, the median age of the patients was 64 (39–86) years, 103 (53.3%) were males and 90 (46.7%) were females, 147 (76.2%) patients had no history of smoking, 185 (96%) patients had an ECOG score between 0 and 1, 168 (87%) patients were stage IV while 25 (13%) patients were stage III, 46 (23.8%) and 85 (44%) patients were diagnosed with brain metastases and bone metastases at baseline, respectively. Genetic analysis revealed that 99 patients (51.3%) had the 19DEL mutation, whereas 94 patients (48.7%) exhibited the L858R mutation.

Clinical characteristics for all patients.

Characteristics PD-L1 (−)(N = 121) PD-L1 (+)(N = 72) P-value
Gender
 Female 56 (46.3%) 34 (47.2%) 1
 Male 65 (53.7%) 38 (52.8%)
Age
 <=65 72 (59.5%) 35 (48.6%) 0.186
 >65 49 (40.5%) 37 (51.4%)
Smoking history
 No 95 (78.5%) 52 (72.2%) 0.414
 Yes 26 (21.5%) 20 (27.8%)
ECOG
 0 49 (40.5%) 24 (33.3%) 0.604
 1 67 (55.4%) 45 (62.5%)
 2 5 (4.1%) 3 (4.2%)
Stage
 III 20 (16.5%) 5 (6.9%) 0.0899
 IV 101 (83.5%) 67 (93.1%)
Brain metastasis
 No 96 (79.3%) 51 (70.8%) 0.243
 Yes 25 (20.7%) 21 (29.2%)
Bone metastasis
 No 74 (61.2%) 34 (47.2%) 0.0826
 Yes 47 (38.8%) 38 (52.8%)
IHC
  22C3 95 (78.5%) 52 (72.2%) 0.414
  SP263 26 (21.5%) 20 (27.8%)
Mutation
 19DEL 67 (55.4%) 32 (44.4%) 0.187
 L858R 54 (44.6%) 40 (55.6%)
TKI Generation
 1 64 (52.9%) 29 (40.3%) 0.236
 2 7 (5.8%) 5 (6.9%)
 3 50 (41.3%) 38 (52.8%)

ECOG, eastern cooperative oncology group; TKI, tyrosine kinase inhibitor.

A total of 88 patients (45.6%) received a third-generation TKI as their first-line treatment. Antiangiogenic combination therapy was used in 91 patients (47.2%), with 31 of these (16.1%) receiving it as a first-line treatment. Among these, 10 patients experienced antiangiogenic combination therapy both in first-line and subsequent-line treatments. Immunotherapy was administered to 25 patients (13%), None received it as their initial treatment. Patients with PD-L1-positive and PD-L1-negative conditions essentially share broadly similar clinical features. PD-L1-positive patients had higher baseline tumor burden, such as higher baseline stage (P = 0.0899) and bone metastases (P = 0.0826).

 Correlation between PD-L1 status and patient outcomes

In the entire study group, the PFS was 15.1 months (ranging from 12.4 to 17.5 months), and the OS was 56.4 months (ranging from 44.4 to 68.4 months). Notably, patients with positive PD-L1 status demonstrated significantly reduced PFS and OS compared to those with negative PD-L1 status, with median PFS at 9.5 months versus 17.8 months (P < 0.0001) and median OS at 44.4 months versus 65.7 months (P = 0.016) as illustrated in Figure 1. Extensive univariate and multivariate Cox regression analyses revealed a consistent and significant link between PD-L1 status and both PFS (P < 0.001) and OS (P = 0.028), as shown in Table 2 and Table 3 respectively. Moreover, the addition of combination antiangiogenic therapy was identified as an independent variable impacting both PFS (P < 0.001) and OS (P = 0.021). Additionally, the presence of brain metastasis at diagnosis was recognized as an independent factor affecting PFS with initial-line therapy (HR 1.76, P = 0.024), along with the use of third-generation TKIs (HR 0.59, P = 0.002) and the L858R mutation (HR 1.54, P = 0.009). In terms of OS, bone metastasis is an independent prognostic factor (HR 1.65, P = 0.039).

(A) Progression-free survival (PFS) and (B) Overall survival (OS) undergoing first-line tyrosine kinase inhibitor (TKI) treatment, analyzed in relation to PD-L1 status.

Univariable and multivariable analysis for progression-free survival (PFS) in all patients.

Univariate analysis Multivariate analysis
Characteristics HR (95% CI) P‐value HR (95% CI) P‐value
PD-L1
 (−) Reference Reference
 (+) 1.90 (1.37–2.63) P < 0.001 1.95 (1.40–2.73) P < 0.001
Gender
 Female Reference —
 Male 1.09 (0.80–1.49) P = 0.587 —
Age
 <=65 Reference —
 >65 0.86 (0.63–1.18) P = 0.339 —
Smoking history
 No Reference —
 Yes 1.02 (0.70–1.47) P = 0.933 —
ECOG
 0 Reference Reference
 1–2 1.50 (1.07–2.10) P = 0.019 1.27 (0.90–1.78) P = 0.178
Stage
 III Reference —
 IV 1.46 (0.91–2.34) P = 0.115 —
Brain
 No Reference Reference
 Yes 1.69 (1.18–2.43) P = 0.005 1.76 (1.21–2.57) P = 0.003
Bone
 No Reference —
 Yes 1.20 (0.87–1.65) P = 0.261 —
Mutation
 19DEL Reference Reference
 L858R 1.48 (1.08–2.03) P = 0.015 1.54 (1.11–2.13) P = 0.009
TKI Generation
 1 Reference Reference
 2 0.82 (0.41–1.62) P = 0.560 0.69 (0.34–1.39) P = 0.298
 3 0.70 (0.50–0.97) P = 0.032 0.59 (0.42–0.83) P = 0.002
1st Line antiangiogenic
 No Reference Reference
 Yes 0.48 (0.30–0.75) P = 0.001 0.40 (0.25–0.63) P < 0.001

ECOG, eastern cooperative oncology group; TKI, tyrosine kinase inhibitor.

Univariable and multivariable analysis for overall survival (OS) in all patients.

Univariate analysis Multivariate analysis
Characteristics HR (95% CI) P‐value HR (95% CI) P‐value
PD-L1
 (−) Reference Reference
 (+) 1.79 (1.11–2.91) P = 0.018 1.74 (1.06–2.84) P = 0.028
Gender
 Female Reference —
 Male 1.27 (0.80–2.03) P = 0.309 —
Age
 <=65 Reference —
 >65 1.35 (0.84–2.15) P = 0.213 —
Smoking history
 No Reference —
 Yes 1.24 (0.72–2.15) P = 0.434 —
ECOG
 0 Reference —
 1–2 1.11 (0.69–1.77) P = 0.673 —
Stage
 III Reference —
 IV 1.06 (0.56–2.02) P = 0.849 —
Brain
 No Reference —
 Yes 1.42 (0.81–2.50) P = 0.221 —
Bone
 No Reference Reference
 Yes 1.69 (1.06–2.71) P = 0.028 1.65 (1.03–2.66) P = 0.039
Mutation
 19DEL Reference Reference
 L858R 1.53 (0.96–2.43) P = 0.073 1.44 (0.90–2.30) P = 0.128
TKI Generation
 1–2 Reference —
 3 1.14 (0.66–1.95) P = 0.644 —
Antiangiogenic
 No Reference Reference
 Yes 0.55 (0.33–0.89) P = 0.015 0.56 (0.34–0.92) P = 0.021
Immunotherapy
 No Reference —
 Yes 0.77 (0.39–1.50) P = 0.436 —

ECOG, eastern cooperative oncology group; TKI, tyrosine kinase inhibitor.

 Subgroup analyses

We subsequently conducted subgroup analyses focusing on PFS and overall survival OS as the endpoint events (Figure 2). For the PFS subgroup, almost all subgroups showed shorter PFS in PD-L1 (+) patients. However, no significant survival differences were detected between PD-L1 (+) and (−) groups within the cohort undergoing first-line antiangiogenic combination therapy (PD-L1 (+) vs. (−): HR 0.95, P = 0.929; P for interaction = 0.096). In the OS subgroup, we found no survival differences between PD-L1 (+) and (−) groups across various patient categories. Notably, this lack of difference was especially pronounced in those on antiangiogenic therapy (PD-L1 (+) vs. (−): HR 1.12, P = 0.753; P for interaction = 0.072), and patients receiving subsequent immunotherapy (PD-L1 (+) vs. (−): HR 0.37, P = 0.228; P for interaction = 0.019). In the treatment with third-generation TKIs, the PFS remained significantly lower in PD-L1 (+) patients (P = 0.002). Although no significant difference in OS was observed between third-generation TKI PD-L1 (+) and PD-L1 (−) patients (P = 0.165), a trend towards worse OS was noted for the PD-L1 (+) group (HR: 2.01, 95% CI 0.75–5.34).

Subgroup analysis of PD-L1 status impact on (A) Progression-free survival (PFS) and (B) Overall survival (OS) across different subgroups in EGFR-Mutant lung cancer patients.

 PD-L1 status-related survival stratified by antiangiogenic therapy

In the first-line treatment, the combination of antiangiogenic therapy with TKI therapy significantly improved PFS, extending it from 12.9 to 22.4 months (P = 0.001) (Figure 3A). This combination therapy also notably enhanced OS throughout the course of treatment, increasing it from 44.5 to 65.7 months (P = 0.014) (Figure 3B). When analyzing PD-L1 status within the patient group receiving antiangiogenic therapy, it was observed that this first-line combination therapy was particularly effective in improving PFS in PD-L1 (+) patients, raising it from 9.1 to 25.7 months (P = 0.026) (Figure 3C). In the same group, the combination markedly boosted OS from 42 to 53.5 months (P = 0.03) (Figure 3D), achieving a median survival time comparable to that of PD-L1 (−) patients. However, for PD-L1 (−) patients specifically, no significant improvement in OS and PFS was observed in antiangiogenic combination therapy group (P > 0.05).

(A) Progression-free survival (PFS) for first-line TKI with/without anti-angiogenics. (B) Overall survival (OS) with anti-angiogenics across all treatments. (C–D) PFS and OS by PD-L1 status with anti-angiogenic use.

 PD-L1 status concerning second-line TKI therapy and subsequent immunotherapy

In our study, after excluding 31 non-progressing patients, 6 with initial T790M mutations, and 46 who didn’t test for the mutation post-resistance, 55 of the remaining 110 patients (50%) developed a T790M mutation following resistance to first-line TKI therapy. Of these, 13 of 33 PD-L1 (+) patients (39.3%) and 42 of 77 PD-L1 (−) patients (54.5%) (P = 0.212) had the mutation. These patients were then treated with second-line TKIs, switching to a third-generation TKI if initially treated with a first-generation TKI. Our analysis showed slightly worse but not statistically significant second-line PFS for PD-L1 (+) patients (9.3 vs. 14.7 months, P = 0.15) (Figure 4A). Additionally, immunotherapy significantly improved overall survival in PD-L1 (+) patients from 42 to 68.4 months (P = 0.011), but not in PD-L1 (−) patients (P = 0.45) (Figures 4B, C).

(A) Progression-free survival (PFS) undergoing second-line tyrosine kinase inhibitor (TKI) treatment, analyzed in relation to PD-L1 status. (B) Overall survival (OS) with immunotherapy use in PD-L1 (+) group. (C) OS with immunotherapy use in PD-L1 (−) group.

 Discussion

The patients harboring EGFR-sensitizing mutations are among those with the best prognosis in advanced NSCLC. However, some subgroups fare worse than others, such as patients who tested positive for both EGFR mutations and PD-L1 before initial therapy. In our retrospective analysis, we examined 193 patients with EGFR-mutated NSCLC receiving first-line TKI therapy across two centers at our institution. After a thorough evaluation of clinicopathological characteristics, we discovered that patients positive for PD-L1 exhibited a shorter PFS and OS compared to PD-L1-negative patients. These findings persisted even after adjustments for multiple factors.

The prognostic significance of PD-L1 expression in EGFR-mutated NSCLC patients, particularly regarding PFS with TKI, remains an area of ongoing research. Most studies (Su et al., 2018; Masuda et al., 2021; Yoshimura et al., 2021; Shiozawa et al., 2022; Hamakawa et al., 2023; Lei et al., 2023) and meta-analyses (Peng et al., 2021) have shown that patients with positive or high PD-L1 expression generally have poorer outcomes. This aligns with our findings, which bodes ill for this group of patients. Interestingly, we have discovered that those receiving first-line combined antiangiogenic therapy negated the impact of prognosis brought by PD-L1 expression, exhibited longer PFS in the PD-L1-positive subgroup.

Concerning OS, the impact of PD-L1 expression warrants further investigation. A meta-analysis indicated a marginally worse prognosis for patients with high PD-L1 expression (P = 0.070) (Peng et al., 2021). Given the proximity of this value to statistical significance and the limited number of studies, we conducted a more detailed analysis of OS across different PD-L1 statuses. Our results revealed a generally worse OS for PD-L1-positive patients overall. However, in subgroups such as patients with initial brain metastases, no significant statistical difference in OS was found. This suggests that the impact of PD-L1 status on OS might be limited. Moreover, we found that in patients who received combined antiangiogenic therapy and subsequent immunotherapy, PD-L1 status had almost no impact on OS. Therefore, although PD-L1 positivity may have a minor impact on prognosis, the combination of antiangiogenic therapy or subsequent immunotherapy effectively mitigated the OS loss in PD-L1 positive patients.

Previous research has primarily focused on the prognostic implications of PD-L1 expression in patients with EGFR-mutated NSCLC. However, there’s a significant gap in understanding how to improve outcomes for patients exhibiting high PD-L1 expression. Our study attempts to contribute to this area of research by exploring the potential efficacy of first-line TKI in combination therapy. We focused on the efficacy of combining first-line TKIs with antiangiogenic therapy, particularly in the context of PD-L1 expression. Our findings reveal that this combination therapy significantly enhances both PFS and OS in PD-L1-positive patients, effectively neutralizing the adverse prognostic effects typically associated with high PD-L1 expression. This improvement is likely due to the observed increase in VEGFA expression among PD-L1-positive lung adenocarcinomas (Koh et al., 2019), a phenomenon also noted in various other cancers (Shin et al., 2016; Koh et al., 2017; Fujii et al., 2020; Yang et al., 2021; Yu et al., 2023). VEGF can influence immune cells in various ways. One notable mechanism is through the enhancement of regulatory T cell (Treg) recruitment and activity, which can modulate immune responses. Furthermore, VEGF and other angiogenic factors such as angiopoietin-2 can impact the functionality of other immune cells, including dendritic cells and macrophages. VEGF can impair the antigen-presenting capacity of dendritic cells and modify their cytokine production, thereby influencing the overall immune response. Intriguingly, antiangiogenic therapy appears to counteract the pro-angiogenic factors stimulated by PD-L1, particularly through the STAT signaling pathway in NSCLC cell lines (Cavazzoni et al., 2024). To our knowledge, this is the first study to stratify the effect of antiangiogenic therapy by PD-L1 expression in EGFR mutant population, and therefore, first-line TKI in combination with antiangiogenic therapy could be a preferable option in the clinic for patients with EGFR mutations who are initially tested positive for PD-L1 or have high expression.

Some studies have suggested a correlation between PD-L1 status and the prevalence of T790M mutations (Yang et al., 2020; Inomata et al., 2022). Our research supports this association, finding that PD-L1-positive patients had fewer T790M mutations. This may give more credit to 3rd generation TKI in the first line setting. Additionally, we observed that PD-L1-positive patients treated with second-line TKIs had slightly worse prognoses, though the differences were not statistically significant. Larger-scale studies are needed to confirm the impact of PD-L1 expression on prognosis in second-line treatments.

Jinfei Si et al. reported that patients treated with immune checkpoint inhibitors (ICIs) in combination with antiangiogenic therapy experienced longer PFS and OS compared to those treated with ICIs and chemotherapy (Si et al., 2023). Yujing Li et al. found that subsequent immunotherapy significantly improved survival in EGFR-mutated patients with high PD-L1 expression after resistance to therapy (Li et al., 2023). In alignment with these findings, our analysis of subsequent ICI treatment according to different PD-L1 statuses revealed that PD-L1-positive patients benefited from immunotherapy even in the presence of EGFR mutation. This supports the use of immunotherapy in patients with high PD-L1 expression and EGFR mutation following the failure of first-line TKI treatment, a benefit not observed in PD-L1-negative patients.

In the field of PD-L1 expression and its prognostic relevance, the determination of a cut-off point remains a subject of debate. While a majority of previous studies have designated 50% as the threshold to differentiate between high and low PD-L1 expression (Hsu et al., 2022; Shiozawa et al., 2022), there is growing evidence of prognostic variances between PD-L1 positivity and negativity (Kobayashi et al., 2018; Hsu et al., 2019; Inomata et al., 2020; Lei et al., 2023). A recent study has proposed that a 20% cut-off point might more accurately reflect these prognostic differences (Hsu et al., 2022). This suggestion is particularly relevant in light of the substantial variability in PD-L1 expression detection caused by different antibodies and experimental conditions. Given that patients with EGFR mutations often exhibit very low PD-L1 expression (Schoenfeld et al., 2020), our study has chosen the 1% criterion. This decision aims to effectively address the heterogeneity issues arising from variations in PD-L1 detection methods, thereby improving the broad applicability and relevance of our findings in the context of diverse clinical scenarios.

One of the current issues is that patients with EGFR mutations are infrequently tested for PD-L1 expression due to the limited efficacy of immunotherapy in these cases. However, based on our findings, we recommend that patients with EGFR mutations undergo PD-L1 expression testing prior to initiating first-line TKI therapy. PD-L1 expression may have predictive value for prognosis and could predict the efficacy of combination anti-angiogenic therapy as well as subsequent immunotherapy.

This study, while offering valuable insights, is subject to certain limitations. Firstly, its retrospective design and relatively small sample size may introduce a degree of selection bias, albeit unintentionally. Secondly, to substantiate our findings more conclusively, we advocate prospective clinical trials designed to address the role of antiangiogenetic agents in patients with both EGFR mutations and PD-L1 expression. Such future research endeavors could provide more definitive evidence and further validate our conclusions.

 Data availability statement

The datasets presented in this article are not readily available because due to confidentiality and ethical considerations, this data is not openly accessible. Requests to access the datasets should be directed to XJ, 2114894356@qq.com.

 Ethics statement

The studies involving humans were approved by Ethics Committee of Sir Run Run Shaw Hospital, part of the School of Medicine at Zhejiang University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

 Author contributions

XJ: Conceptualization, Data curation, Formal Analysis, Writing–original draft, Writing–review and editing. YP: Data curation, Formal Analysis, Writing–original draft. CC: Conceptualization, Data curation, Writing–original draft. HS: Data curation, Formal Analysis, Writing–review and editing. CZ: Formal Analysis, Writing–review and editing. KY: Data curation, Formal Analysis, Writing–review and editing. XZ: Data curation, Formal Analysis, Writing–review and editing. HP: Data curation, Formal Analysis, Funding acquisition, Investigation, Validation, Visualization, Writing–review and editing. LY: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Writing–original draft, Writing–review and editing.

 Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2024.1391972/full#supplementary-material

References Cavazzoni A. Digiacomo G. Volta F. Alfieri R. Giovannetti E. Gnetti L. (2024). PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC). Lung Cancer 187, 107438. 10.1016/j.lungcan.2023.107438 Chen C. L. Wang S. T. Liao W. C. Chen C. H. Tu C. Y. Chen H. J. (2022). When to add anti-angiogenesis drugs to EGFR-mutated metastatic non-small cell lung cancer patients: a real-world study from Taiwan. BMC Cancer 22 (1), 571. 10.1186/s12885-022-09672-4 Fujii T. Hirakata T. Kurozumi S. Tokuda S. Nakazawa Y. Obayashi S. (2020). VEGF-A is associated with the degree of TILs and PD-L1 expression in primary breast cancer. Vivo 34 (5), 2641–2646. 10.21873/invivo.12082 Gainor J. F. Shaw A. T. Sequist L. V. Fu X. Azzoli C. G. Piotrowska Z. (2016). EGFR mutations and alk rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin. Cancer Res. 22 (18), 4585–4593. 10.1158/1078-0432.Ccr-15-3101 Hamakawa Y. Agemi Y. Shiba A. Ikeda T. Higashi Y. Aga M. (2023). Association of PD-L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR-mutated NSCLC. Cancer Med. 12 (17), 17788–17797. 10.1002/cam4.6405 Han R. Guo H. Shi J. Zhao S. Jia Y. Liu X. (2024). Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer. BMC Med. 22 (1), 174. 10.1186/s12916-024-03389-w Hsu K. H. Huang Y. H. Tseng J. S. Chen K. C. Ku W. H. Su K. Y. (2019). High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients. Lung Cancer 127, 37–43. 10.1016/j.lungcan.2018.11.021 Hsu K. H. Tseng J. S. Yang T. Y. Chen K. C. Su K. Y. Yu S. L. (2022). PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. Sci. Rep. 12 (1), 9753. 10.1038/s41598-022-13102-7 Inomata M. Azechi K. Takata N. Hayashi K. Tokui K. Taka C. (2020). Association of tumor PD-L1 expression with the T790M mutation and progression-free survival in patients with EGFR-mutant non-small cell lung cancer receiving EGFR-TKI therapy. Diagn. (Basel) 10 (12), 1006. 10.3390/diagnostics10121006 Inomata M. Matsumoto M. Mizushima I. Seto Z. Hayashi K. Tokui K. (2022). Association of tumor PD-L1 expression with time on treatment using EGFR-TKIs in patients with EGFR-mutant non-small cell lung cancer. Cancer Diagn Progn. 2 (3), 324–329. 10.21873/cdp.10112 Kobayashi K. Seike M. Zou F. Noro R. Chiba M. Ishikawa A. (2018). Prognostic significance of NSCLC and response to EGFR-TKIs of EGFR-mutated NSCLC based on PD-L1 expression. Anticancer Res. 38 (2), 753–762. 10.21873/anticanres.12281 Koh Y. W. Han J. H. Yoon D. H. Suh C. Huh J. (2017). PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma. Ann. Hematol. 96 (11), 1883–1890. 10.1007/s00277-017-3115-6 Koh Y. W. Lee S. J. Han J. H. Haam S. Jung J. Lee H. W. (2019). PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: a study based on immunohistochemistry and RNA sequencing data. Lung Cancer 129, 41–47. 10.1016/j.lungcan.2019.01.004 Lei S. Y. Xu H. Y. Li H. S. Yang Y. N. Xu F. Li J. L. (2023). Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer. Thorac. Cancer 14 (24), 2327–2337. 10.1111/1759-7714.15021 Li Y. Jiang H. Qian F. Chen Y. Zhou W. Zhang Y. (2023). Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance. Front. Immunol. 14, 1161718. 10.3389/fimmu.2023.1161718 Lin C. Chen X. Li M. Liu J. Qi X. Yang W. (2015). Programmed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinoma. Clin. Lung Cancer 16 (5), e25–e35. 10.1016/j.cllc.2015.02.002 Liu J. Itchins M. Nagrial A. Cooper W. A. De Silva M. Barnet M. (2021). Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors. Lung Cancer 155, 28–33. 10.1016/j.lungcan.2021.03.004 Lynch T. J. Bell D. W. Sordella R. Gurubhagavatula S. Okimoto R. A. Brannigan B. W. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (21), 2129–2139. 10.1056/NEJMoa040938 Masuda K. Horinouchi H. Tanaka M. Higashiyama R. Shinno Y. Sato J. (2021). Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression. J. Cancer Res. Clin. Oncol. 147 (1), 245–251. 10.1007/s00432-020-03329-0 Mok T. S. Wu Y. L. Ahn M. J. Garassino M. C. Kim H. R. Ramalingam S. S. (2017). Osimertinib or platinum-pemetrexed in EGFR t790m-positive lung cancer. N. Engl. J. Med. 376 (7), 629–640. 10.1056/NEJMoa1612674 Mok T. S. K. Wu Y. L. Kudaba I. Kowalski D. M. Cho B. C. Turna H. Z. (2019). Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393 (10183), 1819–1830. 10.1016/s0140-6736(18)32409-7 Núñez E. Steyerberg E. W. Núñez J. (2011). Regression modeling strategies. Rev. Esp. Cardiol. 64 (6), 501–507. 10.1016/j.recesp.2011.01.019 Peng Z. Lin H. Zhou K. Deng S. Mei J. (2021). Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis. World J. Surg. Oncol. 19 (1), 145. 10.1186/s12957-021-02254-x Pisapia P. Iaccarino A. De Luca C. Acanfora G. Bellevicine C. Bianco R. (2022). Evaluation of the molecular landscape in PD-L1 positive metastatic NSCLC: data from campania, Italy. Int. J. Mol. Sci. 23 (15), 8541. 10.3390/ijms23158541 Rosell R. Carcereny E. Gervais R. Vergnenegre A. Massuti B. Felip E. (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13 (3), 239–246. 10.1016/s1470-2045(11)70393-x Saito H. Fukuhara T. Furuya N. Watanabe K. Sugawara S. Iwasawa S. (2019). Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 20 (5), 625–635. 10.1016/s1470-2045(19)30035-x Schoenfeld A. J. Rizvi H. Bandlamudi C. Sauter J. L. Travis W. D. Rekhtman N. (2020). Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Ann. Oncol. 31 (5), 599–608. 10.1016/j.annonc.2020.01.065 Seto T. Kato T. Nishio M. Goto K. Atagi S. Hosomi Y. (2014). Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 15 (11), 1236–1244. 10.1016/s1470-2045(14)70381-x Shi Y. Au J. S. Thongprasert S. Srinivasan S. Tsai C. M. Khoa M. T. (2014). A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J. Thorac. Oncol. 9 (2), 154–162. 10.1097/jto.0000000000000033 Shin S. J. Jeon Y. K. Kim P. J. Cho Y. M. Koh J. Chung D. H. (2016). Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell carcinoma: association with oncogenic proteins status. Ann. Surg. Oncol. 23 (2), 694–702. 10.1245/s10434-015-4903-7 Shiozawa T. Numata T. Tamura T. Endo T. Kaburagi T. Yamamoto Y. (2022). Prognostic implication of PD-L1 expression on osimertinib treatment for EGFR-mutated non-small cell lung cancer. Anticancer Res. 42 (5), 2583–2590. 10.21873/anticanres.15736 Si J. Hao Y. Wei J. Xiang J. Xu C. Shen Q. (2023). Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations. BMC Pulm. Med. 23 (1), 158. 10.1186/s12890-023-02466-9 Soo R. A. Lim S. M. Syn N. L. Teng R. Soong R. Mok T. S. K. (2018). Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: current controversies and future directions. Lung Cancer 115, 12–20. 10.1016/j.lungcan.2017.11.009 Su S. Dong Z. Y. Xie Z. Yan L. X. Li Y. F. Su J. (2018). Strong programmed death ligand 1 expression predicts poor response and de novo resistance to EGFR tyrosine kinase inhibitors among NSCLC patients with EGFR mutation. J. Thorac. Oncol. 13 (11), 1668–1675. 10.1016/j.jtho.2018.07.016 Tsai J. S. Su P. L. Yang S. C. Chang C. C. Lin C. Y. Yen Y. T. (2021). EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis. J. Formos. Med. Assoc. 120 (9), 1729–1739. 10.1016/j.jfma.2021.03.023 Yang C. Y. Liao W. Y. Ho C. C. Chen K. Y. Tsai T. H. Hsu C. L. (2020). Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. Eur. J. Cancer 124, 110–122. 10.1016/j.ejca.2019.10.019 Yang Y. Xia L. Wu Y. Zhou H. Chen X. Li H. (2021). Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer. Cancer Commun. (Lond). 41 (6), 511–527. 10.1002/cac2.12157 Yoshimura A. Yamada T. Okuma Y. Fukuda A. Watanabe S. Nishioka N. (2021). Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study. Transl. Lung Cancer Res. 10 (8), 3582–3593. 10.21037/tlcr-21-461 You L. Zheng X. Deng D. Pan H. Han W. (2022). The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study. Sci. Rep. 12 (1), 14624. 10.1038/s41598-022-18889-z Yu J. Zhuang A. Gu X. Hua Y. Yang L. Ge S. (2023). Nuclear PD-L1 promotes EGR1-mediated angiogenesis and accelerates tumorigenesis. Cell Discov. 9 (1), 33. 10.1038/s41421-023-00521-7